XTL Biopharma Subsidiary Sees CEO & CTO Resign
Ticker: XTLB · Form: 6-K · Filed: Dec 12, 2025 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, subsidiary
TL;DR
XTL Biopharma's subsidiary Social Proxy Ltd. lost its CEO & CTO on Dec 11th, company figuring out next steps.
AI Summary
On December 11, 2025, Tal Klinger, CEO of Social Proxy Ltd., and Roee Klinger, CTO of Social Proxy Ltd., both wholly owned subsidiaries of XTL Biopharmaceuticals Ltd., submitted their immediate resignations. XTL Biopharmaceuticals is currently assessing the next steps for managing Social Proxy Ltd.
Why It Matters
The sudden departure of key management from a subsidiary could impact its operations and XTL Biopharmaceuticals' overall strategy and financial performance.
Risk Assessment
Risk Level: medium — The resignation of key executives from a subsidiary creates uncertainty regarding the subsidiary's future operations and management, potentially impacting the parent company.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Filer and parent company
- Social Proxy Ltd. (company) — Wholly owned subsidiary of XTL Biopharmaceuticals Ltd.
- Tal Klinger (person) — Former CEO of Social Proxy Ltd.
- Roee Klinger (person) — Former CTO of Social Proxy Ltd.
- December 11, 2025 (date) — Date of resignations
FAQ
Who resigned from their positions?
Tal Klinger, Chief Executive Officer of Social Proxy Ltd., and Roee Klinger, Chief Technology Officer of Social Proxy Ltd., resigned.
When were the resignations effective?
The resignations were effective immediately upon submission on December 11, 2025.
What is the relationship between XTL Biopharmaceuticals Ltd. and Social Proxy Ltd.?
Social Proxy Ltd. is a wholly owned subsidiary of XTL Biopharmaceuticals Ltd.
What is XTL Biopharmaceuticals Ltd. doing in response to the resignations?
The Company is evaluating next steps with respect to the management of Social Proxy Ltd.
What is the filing date of this report?
This Form 6-K was filed as of December 12, 2025.
Filing Stats: 209 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-12-12 17:25:01
Filing Documents
- ea0269577-6k_xtlbio.htm (6-K) — 9KB
- 0001213900-25-121299.txt ( ) — 10KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: December 12, 2025 By: /s/ Noam Band Noam Band Chief Executive Officer 2